Acadia Pharmaceuticals Inc

NASDAQ: ACAD
$17.66
+$0.46 (+2.7%)
Closing Price on November 8, 2024

ACAD Articles

Acadia Pharmaceuticals reported its second-quarter financial results after the markets closed on Tuesday.
After Acadia Pharmaceuticals released its third-quarter earnings report after the markets closed on Monday, shares rose sharply Tuesday morning.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include AT&T, CenturyLink, Goldman Sachs, OneMain and Priceline.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include CenturyLink, Gold Fields, Papa John's, Priceline, SolarCity, Tesla Motors and Unisys.
A Merrill Lynch report has a whole wave of companies featured as Global Ageing Primer Picks, including these biotech and pharmaceutical picks.
Despite the fact that first-quarter earnings will come in big next week, some serious insider buying has hit the tape.
Over the past week, Opko Health, Acadia Pharmaceuticals and a few other biotech companies made impressive runs.
Acadia Pharmaceuticals saw its shares on the rise again this week following an incredibly positive FDA vote on its Parkinson's treatment.
Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) surged early on Monday morning. This company is under the spotlight by the U.S. Food and Drug Administration’s Psychopharmacologic Drugs...
24/7 Wall St. has collected three big FDA decisions coming up in March and added some color, along with the trading range and price target.
Here are six biotech and pharma stocks that analysts are telling their firm's clients to buy now for solid upside opportunities ahead.
The top analyst upgrades, downgrades and initiations seen on Monday, February 8 include Athenahealth, Baker Hughes, Cisco, LinkedIn, Orbital-ATK and Tableau Software.
Thursday's top analyst upgrades, downgrades and initiations include Amazon.com, Monsanto, Schlumberger, SolarCity, Western Digital, Yelp, Abercrombie & Fitch.
Thursday's top analyst upgrades, downgrades and initiations include Alcatel-Lucent, Apple, Coach, Etsy, Intel, MannKind, Netflix, SanDisk and Starbucks.
Here are the five biotech stocks that are loved the most by portfolio managers, according to Cowen analysts.